John Quelch - Alerislife Independent Director
| ALRDelisted Stock | USD 1.32 0.00 0.00% |
Director
Prof. Dr. John A. Quelch, Ph.D. is Independent Director of the Company. He was the Charles Edward Wilson Professor of Business Administration at Harvard Business School and professor in Health Policy and Management at Harvard School of Public Health since January 2013. Between February 2011 and January 2013, Dr. Quelch served as Dean, Vice President and Distinguished Professor of International Management at the China Europe International Business School in Shanghai. From July 2001 through January 2011, he was professor and Senior Associate Dean at the Harvard Business School. From July 1998 through June 2001, he was Dean of the London Business School. Dr. Quelch also serves as a director of Aramark, a food service, facilities management and uniforms company, and Luvo Inc., a privately held retail food products company. Dr. Quelch served as a director of WPP plc from 1988 to 2013, Pepsi Bottling Group from 2005 to 2010 and Gentiva Health Services, Inc. from 2006 to 2009. since 2003.
| Age | 64 |
| Tenure | 21 years |
| Phone | 617 796 8387 |
| Web | https://www.alerislife.com |
Alerislife Management Efficiency
The company has Return on Asset of (0.0497) % which means that on every $100 spent on assets, it lost $0.0497. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2183) %, meaning that it generated no profit with money invested by stockholders. Alerislife's management efficiency ratios could be used to measure how well Alerislife manages its routine affairs as well as how well it operates its assets and liabilities.The company has 9.41 M in debt with debt to equity (D/E) ratio of 0.48, which is OK given its current industry classification. Alerislife has a current ratio of 1.66, which is typical for the industry and considered as normal. Debt can assist Alerislife until it has trouble settling it off, either with new capital or with free cash flow. So, Alerislife's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alerislife sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alerislife to invest in growth at high rates of return. When we think about Alerislife's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Aod Moraes | Gerdau SA ADR | 52 | |
| Glyn Barker | Transocean | 67 | |
| Frederick Mohn | Transocean | 43 | |
| Susan Davis | Quanex Building Products | 67 | |
| Fernando Iunes | Gerdau SA ADR | 57 | |
| Richard Johannpeter | Gerdau SA ADR | 45 | |
| Joseph Rupp | Quanex Building Products | 70 | |
| Frederico Curado | Transocean | 59 | |
| Chad Deaton | Transocean | 61 | |
| Donald Maier | Quanex Building Products | 56 | |
| Martin McNamara | Transocean | 68 | |
| Robert Iversen | Superior Drilling Products | 62 | |
| Fabio Spina | Gerdau SA ADR | 52 | |
| Edward Muller | Transocean | 68 | |
| Claudia Ramirez | Gerdau SA ADR | 43 | |
| Alfredo Huallem | Gerdau SA ADR | 66 | |
| Robert Buck | Quanex Building Products | 72 | |
| William Waltz | Quanex Building Products | 56 | |
| LeRoy Nosbaum | Quanex Building Products | 70 | |
| Jason Lippert | Quanex Building Products | 48 | |
| Terence Cryan | Superior Drilling Products | 53 | |
Management Performance
| Return On Equity | -0.22 | |||
| Return On Asset | -0.0497 |
Alerislife Leadership Team
Elected by the shareholders, the Alerislife's board of directors comprises two types of representatives: Alerislife inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alerislife. The board's role is to monitor Alerislife's management team and ensure that shareholders' interests are well served. Alerislife's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alerislife's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Juliet Cunningham, VP of Investor Relations | ||
| Malgorzata Bartler, Deputy CEO, Vice Chairman of the Management Board | ||
| Sylwester Grzebinoga, Vice Chairman of the Management Board | ||
| Piotr Bystrzanowski, Head of Investor Relations | ||
| Jeffrey Leer, Pres CEO | ||
| Marcin Eckert, Member of the Supervisory Board | ||
| John Quelch, Independent Director | ||
| Dariusz Gatarek, Independent Member of the Supervisory Board | ||
| Michal Chyczewski, Vice Chairman of the Management Board | ||
| Pawel Szymanski, Independent Member of the Supervisory Board | ||
| John Martin, Non-Executive Independent Director | ||
| Brian Sherman, Chairman of the Board | ||
| Slawomir Niemierka, Member of the Supervisory Board | ||
| Philip Benjamson, VP COO | ||
| Krzysztof Czuba, Deputy CEO, Vice Chairman of the Management Board | ||
| Jennifer Clark, S MD | ||
| Neville Miles, Independent Non-Executive Director | ||
| Malgorzata IwaniczDrozdowska, Independent Vice Chairman of the Supervisory Board | ||
| Katarzyna Sulkowska, Deputy CEO, Vice Chairman of the Management Board | ||
| Marcin Jaszczuk, Vice Chairman of the Management Board | ||
| Joanna Krzyzanowska, Deputy CEO, Vice Chairman of the Management Board | ||
| Agata Strzelecka, Vice Chairman of the Management Board | ||
| Stephen Geiger, VP Officer | ||
| Vijay Moses, Sr Counsel | ||
| Gil Orski, Company Secretary | ||
| Ellen Chiniara, Vice President General Counsel, Secretary | ||
| Gregg Powers, Independent Director | ||
| Celina Waleskiewicz, Vice Chairman of the Management Board | ||
| Artur Kucharski, Independent Member of the Supervisory Board | ||
| Marek Szczesniak, Vice Chairman of the Management Board | ||
| Carol Goldberg, Independent Director | ||
| Hakan Bjorklund, Independent Director | ||
| Mateusz Poznanski, Vice Chairman of the Management Board | ||
| Mark Gladwell, Sr. VP of Global Operations | ||
| Filip Gorczyca, Vice Chairman of the Management Board | ||
| Heather Pereira, Treasurer VP | ||
| John Bridgen, Senior Vice President - Business Development | ||
| Mikolaj Handschke, Independent Member of the Supervisory Board | ||
| Seweryn Kowalczyk, Vice Chairman of the Management Board | ||
| Melissa Guerdan, Vice President-Global Quality Assurance | ||
| Tomasz Bilous, Vice Chairman of the Management Board | ||
| Renuka Uppaluri, Senior Vice President - Global Research and Development | ||
| James Kotarski, VP Officer | ||
| Adam Portnoy, Chairman MD | ||
| Namal Nawana, CEO and President and Director | ||
| Timothy Bonang, VP Relations | ||
| Tomasz Kulik, Chairman of the Supervisory Board | ||
| Stephen MacMillan, Independent Director | ||
| Brian Markison, Independent Director | ||
| Wojciech Sobieraj, Chairman of the Management Board, CEO | ||
| Maciej Surdyk, Vice Chairman of the Management Board | ||
| Susan Dooley, VP Marketing | ||
| Barry Sechos, Director | ||
| Barbara Smalska, Deputy CEO, Vice Chairman of the Management Board | ||
| James Roosevelt, Independent Director | ||
| Jonathan Wygant, Chief Accounting Officer | ||
| Sanjay Malkani, Global President of Toxicology | ||
| Maciej Rapkiewicz, Member of the Supervisory Board | ||
| James Hinrichs, CFO and Executive VP | ||
| Robert Hargadon, Vice President - Global Culture and Performance | ||
| Krzysztof Bachta, Vice Chairman of the Management Board | ||
| Wojciech Myslecki, Member of the Supervisory Board | ||
| Thomas McKillop, Independent Director | ||
| Geoffrey Ginsburg, Director | ||
| Augustine Daniels, Executive Director | ||
| Daniella Cramp, Global President of Cardiometabolic Bus. Unit | ||
| David Sokulsky, CEO, Chief Investment Officer | ||
| Urszula KrzyzanowskaPiekos, Vice Chairman of the Management Board | ||
| Witold Skrok, Deputy CEO, Vice Chairman of the Management Board for Finance | ||
| Regina Benjamin, Independent Director | ||
| Dariusz Szwed, Vice Chairman of the Management Board | ||
| Avi Pelossof, Global President of Infectious Disease Bus. Unit | ||
| Carla Flakne, Chief Accounting Officer and VP | ||
| John Levy, Independent Director |
Alerislife Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alerislife a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | |||
| Return On Asset | -0.0497 | |||
| Profit Margin | (0.24) % | |||
| Operating Margin | (0.19) % | |||
| Current Valuation | 17.82 M | |||
| Shares Outstanding | 33.47 M | |||
| Shares Owned By Insiders | 41.00 % | |||
| Shares Owned By Institutions | 18.80 % | |||
| Number Of Shares Shorted | 66.54 K | |||
| Price To Earning | (16.02) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alerislife in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alerislife's short interest history, or implied volatility extrapolated from Alerislife options trading.
Pair Trading with Alerislife
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alerislife position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alerislife will appreciate offsetting losses from the drop in the long position's value.Moving together with Alerislife Stock
| 0.69 | NVDA | NVIDIA Buyout Trend | PairCorr |
| 0.65 | GOOG | Alphabet Class C Buyout Trend | PairCorr |
| 0.68 | AMZN | Amazon Inc Aggressive Push | PairCorr |
Moving against Alerislife Stock
| 0.87 | BA | Boeing Financial Report 24th of July 2024 | PairCorr |
| 0.84 | MCD | McDonalds Financial Report 25th of July 2024 | PairCorr |
| 0.77 | AAPL | Apple Inc Earnings Call This Week | PairCorr |
| 0.64 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.62 | INTC | Intel Financial Report 25th of July 2024 | PairCorr |
The ability to find closely correlated positions to Alerislife could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alerislife when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alerislife - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alerislife to buy it.
The correlation of Alerislife is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alerislife moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alerislife moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alerislife can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Alerislife Stock
If you are still planning to invest in Alerislife check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alerislife's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |